Discovery - University of Dundee - Online Publications

Library & Learning Centre

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 Diabetes

Standard

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 Diabetes : an analysis from the CARDS trial. / Colhoun, Helen M. (Lead / Corresponding author); Betteridge, D. John; Durrington, Paul; Hitman, Graham; Neil, Andrew; Livingstone, Shona; Charlton-Menys, Valentine; Bao, Weihang; DeMicco, David A.; Preston, Gregory M.; Deshmukh, Harshal; Tan, Kathryn; Fuller, John H.

In: Diabetes, Vol. 60, No. 9, 09.2011, p. 2379-2385.

Research output: Contribution to journalArticle

Harvard

Colhoun, HM, Betteridge, DJ, Durrington, P, Hitman, G, Neil, A, Livingstone, S, Charlton-Menys, V, Bao, W, DeMicco, DA, Preston, GM, Deshmukh, H, Tan, K & Fuller, JH 2011, 'Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 Diabetes: an analysis from the CARDS trial' Diabetes, vol 60, no. 9, pp. 2379-2385.

APA

Colhoun, H. M., Betteridge, D. J., Durrington, P., Hitman, G., Neil, A., Livingstone, S., Charlton-Menys, V., Bao, W., DeMicco, D. A., Preston, G. M., Deshmukh, H., Tan, K., & Fuller, J. H. (2011). Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 Diabetes: an analysis from the CARDS trial. Diabetes, 60(9), 2379-2385doi: 10.2337/db11-0291

Vancouver

Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 Diabetes: an analysis from the CARDS trial. Diabetes. 2011 Sep;60(9):2379-2385.

Author

Colhoun, Helen M. (Lead / Corresponding author); Betteridge, D. John; Durrington, Paul; Hitman, Graham; Neil, Andrew; Livingstone, Shona; Charlton-Menys, Valentine; Bao, Weihang; DeMicco, David A.; Preston, Gregory M.; Deshmukh, Harshal; Tan, Kathryn; Fuller, John H. / Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 Diabetes : an analysis from the CARDS trial.

In: Diabetes, Vol. 60, No. 9, 09.2011, p. 2379-2385.

Research output: Contribution to journalArticle

Bibtex - Download

@article{0999968ae8a141f2b0c1784cb78b2ef2,
title = "Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 Diabetes",
author = "Colhoun, {Helen M.} and Betteridge, {D. John} and Paul Durrington and Graham Hitman and Andrew Neil and Shona Livingstone and Valentine Charlton-Menys and Weihang Bao and DeMicco, {David A.} and Preston, {Gregory M.} and Harshal Deshmukh and Kathryn Tan and Fuller, {John H.}",
year = "2011",
volume = "60",
number = "9",
pages = "2379--2385",
journal = "Diabetes",
issn = "0012-1797",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 Diabetes

T2 - an analysis from the CARDS trial

A1 - Colhoun,Helen M.

A1 - Betteridge,D. John

A1 - Durrington,Paul

A1 - Hitman,Graham

A1 - Neil,Andrew

A1 - Livingstone,Shona

A1 - Charlton-Menys,Valentine

A1 - Bao,Weihang

A1 - DeMicco,David A.

A1 - Preston,Gregory M.

A1 - Deshmukh,Harshal

A1 - Tan,Kathryn

A1 - Fuller,John H.

AU - Colhoun,Helen M.

AU - Betteridge,D. John

AU - Durrington,Paul

AU - Hitman,Graham

AU - Neil,Andrew

AU - Livingstone,Shona

AU - Charlton-Menys,Valentine

AU - Bao,Weihang

AU - DeMicco,David A.

AU - Preston,Gregory M.

AU - Deshmukh,Harshal

AU - Tan,Kathryn

AU - Fuller,John H.

PY - 2011/9

Y1 - 2011/9

N2 - <p>OBJECTIVE-Circulating levels of soluble receptor for advanced glycation end products (sRAGE) likely comprise both a secreted isoforrn (esRAGE) and wild-type RAGE cleaved from the cell membrane. Both sRAGE and esRAGE have been proposed as biomarkers of cardiovascular disease (CVD), but prospective data are limited. We examined the relationship of sRAGE and esRAGE to incident coronary heart disease (CHD) and stroke in type 2 diabetic patients followed for 3.9 years in a trial of atorvastatin: the Collaborative Atorvastatin Diabetes Study (CARDS).</p><p>RESEARCH DESIGN AND METHODS-We used a nested case-control design sampling all incident cases of CVD with available plasma and randomly selecting three control subjects, who were free of CVD throughout follow-up, per case. Analysis was by Cox regression with adjustment for treatment allocation and relevant covariates.</p><p>RESULTS-sRAGE and esRAGE were strongly correlated (rho = 0.88) and were both higher in those with lower BMI (P &lt; 0.001), higher adiponectin (P &lt; 0.001), lower estimated glomerular filtration rate (P = 0.009), and white ethnicity (P &lt; 0.001). Both sRAGE and esRAGE were associated with incident CHD events, independently of treatment allocation and the above factors; hazard ratio (HR) = 1.74 (95% CI 1.25-2.41; P = 0.002) for a doubling of the sRAGE level; HR = 1.45 (1.11-1.89; P = 0.006) for a doubling of the esRAGE level. There was no significant association with stroke; HR for sRAGE = 0.66 (0.38-1.14). Atorvastatin, 10 mg daily, did not alter sRAGE.</p><p>CONCLUSIONS-Higher levels of sRAGE and esRAGE are associated with incident CHD but not stroke in type 2 diabetes. Diabetes 60:2379-2385, 2011</p>

AB - <p>OBJECTIVE-Circulating levels of soluble receptor for advanced glycation end products (sRAGE) likely comprise both a secreted isoforrn (esRAGE) and wild-type RAGE cleaved from the cell membrane. Both sRAGE and esRAGE have been proposed as biomarkers of cardiovascular disease (CVD), but prospective data are limited. We examined the relationship of sRAGE and esRAGE to incident coronary heart disease (CHD) and stroke in type 2 diabetic patients followed for 3.9 years in a trial of atorvastatin: the Collaborative Atorvastatin Diabetes Study (CARDS).</p><p>RESEARCH DESIGN AND METHODS-We used a nested case-control design sampling all incident cases of CVD with available plasma and randomly selecting three control subjects, who were free of CVD throughout follow-up, per case. Analysis was by Cox regression with adjustment for treatment allocation and relevant covariates.</p><p>RESULTS-sRAGE and esRAGE were strongly correlated (rho = 0.88) and were both higher in those with lower BMI (P &lt; 0.001), higher adiponectin (P &lt; 0.001), lower estimated glomerular filtration rate (P = 0.009), and white ethnicity (P &lt; 0.001). Both sRAGE and esRAGE were associated with incident CHD events, independently of treatment allocation and the above factors; hazard ratio (HR) = 1.74 (95% CI 1.25-2.41; P = 0.002) for a doubling of the sRAGE level; HR = 1.45 (1.11-1.89; P = 0.006) for a doubling of the esRAGE level. There was no significant association with stroke; HR for sRAGE = 0.66 (0.38-1.14). Atorvastatin, 10 mg daily, did not alter sRAGE.</p><p>CONCLUSIONS-Higher levels of sRAGE and esRAGE are associated with incident CHD but not stroke in type 2 diabetes. Diabetes 60:2379-2385, 2011</p>

KW - Cardiovascular disease

KW - Endproducts rage

KW - Association

KW - Atherosclerosis

KW - Complications

KW - Failure

KW - Level

KW - Srage

KW - Gene

KW - Form

U2 - 10.2337/db11-0291

DO - 10.2337/db11-0291

M1 - Article

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 9

VL - 60

SP - 2379

EP - 2385

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy